NCT06183944 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Duffett L, Castellucci LA, Forgie MA
Pulmonary embolism: update on management and controversies. BMJ. 2020 Aug 5;370:m2177. doi: 10.1136/bmj.m2177.
Gal J, Bailleux C, Chardin D, Pourcher T, Gilhodes J, Jing L, Guigonis JM, Ferrero JM, Milano G, Mograbi B, Brest P, Chateau Y, Humbert O, Chamorey E
Comparison of unsupervised machine-learning methods to identify metabolomic signatures in patients with localized breast cancer. Comput Struct Biotechnol J. 2020 Jun 3;18:1509-1524. doi: 10.1016/j.csbj.2020.05.021. eCollection 2020.
Gallo A, Valerio L, Barco S
The 2019 European guidelines on pulmonary embolism illustrated with the aid of an exemplary case report. Eur Heart J Case Rep. 2021 Jan 4;5(2):ytaa542. doi: 10.1093/ehjcr/ytaa542. eCollection 2021 Feb.
Schiappa R, Contu S, Culie D, Chateau Y, Gal J, Pace-Loscos T, Bailleux C, Haudebourg J, Ferrero JM, Barranger E, Chamorey E
Validation of RUBY for Breast Cancer Knowledge Extraction From a Large French Electronic Medical Record System. JCO Clin Cancer Inform. 2023 May;7:e2200130. doi: 10.1200/CCI.22.00130.
Yu T, Shen R, You G, Lv L, Kang S, Wang X, Xu J, Zhu D, Xia Z, Zheng J, Huang K
Machine learning-based prediction of the post-thrombotic syndrome: Model development and validation study. Front Cardiovasc Med. 2022 Sep 16;9:990788. doi: 10.3389/fcvm.2022.990788. eCollection 2022.

Data Acquisition Study With Artificial Intelligence and Phenotyping of Patients Who Presented With Acute Pulmonary Embolism

Clinical trial NCT06183944 - References